HC Wainwright & Co. Maintains Buy on Fulcrum Therapeutics, Raises Price Target to $25
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew S. Fein maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $18 to $25.
HC Wainwright & Co. analyst Andrew S. Fein maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price target from $18 to $25.